Pharmaceutical Executive: April 2026

View the Pharmaceutical Executive April 2026 issue in an interactive format.

Our April issue's feature profile offers a reminder that, increasingly, the CFO role in pharma is not just about stewardship but about shaping direction.

In becoming the first CFO to be named HBA Woman of the Year, AstraZeneca's Aradhana Sarin highlights how financial leadership now sits at the center of innovation, access and strategic transformation.

Dismissing the role of independent, outside experts in FDA decision-making weakens the drug review process.

The agentic model is emerging as a strategic tool to compress analysis timelines, coordinate cross-functional teams and surface competitive intelligence in real time.

Where PBMs fit into the new market access landscape, how pharma companies can respond and the questions that remain.

The importance of aligning cost control with clinical appropriateness and continuity of care.

RWD can bolster natural history studies with insight to longitudinal, real-time disease progression.

Greater Miami is rapidly emerging as an international biotech hot spot—as capital, talent, and infrastructure converge to transform the region from a tourism-driven economy into a globally connected life sciences innovation hub.